Clinicopathological characteristics and prognostic outcomes in consecutive Japanese patients with high microsatellite-instability colorectal cancer: real-world data from universal screening

High microsatellite instability (MSI-H) is an established prognostic marker in various cancers, including colorectal, gastric, and endometrial cancers. However, comprehensive real-world data from universal screening in Asian populations remain limited. We aimed to evaluate the clinicopathological and prognostic impact of MSI-H status in Japanese patients with colorectal cancer (CRC). This retrospective cohort study was conducted at Osaka General Medical Center, Japan. A total of 346 consecutive patients with CRC who underwent MSI testing between January 2021 and December 2022 were retrospectively analyzed. MSI status and associated clinicopathological features were assessed. Overall survival (OS) and recurrence-free survival (RFS) were analyzed using Kaplan–Meier survival curves and Cox regression models. Among the 346 patients, 29 (8.4%) had MSI-H tumors, which were more frequently right-sided (p <0.0001) and poorly differentiated (p <0.0001) compared with non-MSI-H. Genomic analysis revealed that MSI-H tumors had significantly fewer RAS mutations (p = 0.024) and more BRAF mutations (p <0.0001) compared with non-MSI-H tumors. Survival analysis showed no significant differences in RFS (HR, 0.67; 95% CI, 0.26–1.90; p = 0.40) or OS (HR, 0.64; 95% CI, 0.30–1.58; p = 0.78) between patients with MSI-H and non–MSI-H tumors. Multivariate analysis identified MSI-H as a potential independent predictor of favorable OS (HR, 0.07; 95% CI, 0.005–0.90; p = 0.04), whereas BRAF mutations were associated with poor OS (HR, 7.39; 95% CI, 1.32–41.50; p = 0.02). This real-world study suggests that MSI-H status is associated with distinct clinicopathological characteristics and may be associated with improved overall survival in Japanese patients with CRC undergoing universal MSI screening. These findings support the clinical relevance of MSI testing in routine clinical practice and highlight the need for further validation in a larger cohort.

Authors

Institutions

Publication Details

Journal
BMC Gastroenterology
Published
2026-03-13
DOI
https://doi.org/10.1186/s12876-026-04696-7
Primary Topic
Genetic factors in colorectal cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinicopathological characteristics and prognostic outcomes in consecutive Japanese patients with high microsatellite-instability colorectal cancer: real-world data from universal screening

Yujiro Nishizawa, Masaaki Motoori, Akira Tomokuni, Yuki Ozato et al.
BMC Gastroenterology
Genetic factors in colorectal cancer
article

Clinicopathological characteristics and prognostic outcomes in consecutive Japanese patients with high microsatellite-instability colorectal cancer: real-world data from universal screening

Yujiro Nishizawa, Masaaki Motoori, Akira Tomokuni, Yuki Ozato, Yasuhiro Miyazaki, Kenta Furukawa, Masashi Hirota, Yoshihiro Morimoto, Kazumasa Fujitani, Akira Inoue, Masahiro Hashimoto
article en

Abstract

High microsatellite instability (MSI-H) is an established prognostic marker in various cancers, including colorectal, gastric, and endometrial cancers. However, comprehensive real-world data from universal screening in Asian populations remain limited. We aimed to evaluate the clinicopathological and prognostic impact of MSI-H status in Japanese patients with colorectal cancer (CRC). This retrospective cohort study was conducted at Osaka General Medical Center, Japan. A total of 346 consecutive patients with CRC who underwent MSI testing between January 2021 and December 2022 were retrospectively analyzed. MSI status and associated clinicopathological features were assessed. Overall survival (OS) and recurrence-free survival (RFS) were analyzed using Kaplan–Meier survival curves and Cox regression models. Among the 346 patients, 29 (8.4%) had MSI-H tumors, which were more frequently right-sided (p <0.0001) and poorly differentiated (p <0.0001) compared with non-MSI-H. Genomic analysis revealed that MSI-H tumors had significantly fewer RAS mutations (p = 0.024) and more BRAF mutations (p <0.0001) compared with non-MSI-H tumors. Survival analysis showed no significant differences in RFS (HR, 0.67; 95% CI, 0.26–1.90; p = 0.40) or OS (HR, 0.64; 95% CI, 0.30–1.58; p = 0.78) between patients with MSI-H and non–MSI-H tumors. Multivariate analysis identified MSI-H as a potential independent predictor of favorable OS (HR, 0.07; 95% CI, 0.005–0.90; p = 0.04), whereas BRAF mutations were associated with poor OS (HR, 7.39; 95% CI, 1.32–41.50; p = 0.02). This real-world study suggests that MSI-H status is associated with distinct clinicopathological characteristics and may be associated with improved overall survival in Japanese patients with CRC undergoing universal MSI screening. These findings support the clinical relevance of MSI testing in routine clinical practice and highlight the need for further validation in a larger cohort.

BMC Gastroenterology
Osaka City University (JP), Osaka City General Hospital (JP)
Good health and well-being
Openalex Percentile: Top 25%
Genetic factors in colorectal cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.